E-News - October 2022
ASCO Plenary Series

OCTOBER ASCO PLENARY SERIES TO FEATURE PALLAS (AFT-05) STUDY UPDATE

Alliance Foundation Trials, LLC, is pleased to announce that an update of the Palbociclib Collaborative Adjuvant Study (PALLAS/AFT-05) led by Co-Principal Investigators Erica L. Mayer, MD, MPH (AFT/Dana-Farber Cancer Institute) and Angela DeMichele, MD, MSCE (PrECOG/University of Pennsylvania) will be presented by Dr. DeMichele at 3 pm ET October 18, 2022, as part of the monthly American Society of Clinical Oncology Virtual Plenary Series.

The PALLAS study compares palbociclib plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy alone in women and men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative

(HER2-) early (stage 2 and 3) breast cancer and is an academically-led global collaboration, involving more than 400 centers in 21 countries around the globe. The study is co-sponsored by the Austrian Breast & Colorectal Cancer Study Group and Alliance Foundation Trials as part of a clinical research collaboration with Pfizer and other study groups, including PrECOG, LLC; NSABP Foundation Inc; and the Breast International Group (BIG). 

In May 2020, an interim analysis showed that the study was unlikely to meet its primary endpoint. During the October ASCO Plenary Series, Dr. DeMichele will deliver the results of a pre-planned analysis of the cohort of patients diagnosed with stage 2A disease.

The ASCO Plenary Series will feature a panel question and answer session with Dr. DeMichele, Alliance patient advocate Jane Perlmutter, PhD, MBA, and other guests, moderated by Alliance investigator Toni Chouieri, MD (Dana-Farber Cancer Institute). 

Join in to participate in the series here. 

ClinicalTrials.gov Identifier: NCT02513394. PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer